LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 28, 2013--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued patent 8,368,402 (the ‘402 patent), “NMR systems for in vivo detection of analytes”. This patent covers the use of the Company’s T2MR ® technology in an implantable device for the in vivo monitoring of a target analyte.
“T2MR technology provides the power to directly detect a target analyte and can be applied to many applications, including detection within the patient’s body,” said John McDonough, President and CEO, T2 Biosystems. “ In vivo utilization is a potential application of our core T2MR technology that may ultimately allow patients, especially those with chronic illnesses, to forego routine diagnostic procedures and would provide physicians and patients with rapid, real-time results, enabling more effective treatment decisions.” McDonough continued, “Our T2MR innovations incorporate a broad array of applications that include bench-top instruments, portable and point-of-care devices, and at-home patient diagnostics.” The ‘402 patent covers a method for assessing the presence or concentration of a target analyte contained in a body fluid of a mammal in vivo using an implantable T2MR sensor, a MR reader positioned outside the mammal’s body and the detection of the presence or concentration of analyte in the sample. T2 Biosystems now owns or has rights to 20 worldwide patents.
About T2 Biosystems
T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR ®, the Company’s proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company’s products detect molecular or immunoassay targets as well as hemostasis biomarkers directly from unpurified clinical samples in hospitals, labs and physicians’ offices. For more information, please visit www.t2biosystems.com.